Abstract: The present invention provides a hydrophobic group-introduced hyaluronic acid derivative comprising at least one repeating unit represented by the formula (I): wherein R1, R2, R3, R4, Z, n, Ra, Y, and X1 are as defined in the specification.

Abstract: The present invention synthetic oligo-?-(1?6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-?-(1?6)-glucosamine species having a definite number of monosaccharide units, including a set pattern of acetylated and non-acetylated residues. The invention further provides antibodies to these synthetic oligo-?-(1?6)-glucosamines as well as compositions thereof and methods for treating and preventing infections caused by bacteria expressing poly-?-(1?6)-glucosamines, such as Staphylococcus aureus.

Abstract: Disclosed are a polysaccharide derivative obtained by substituting some of the carboxyl groups of a carboxy polysaccharide with —NH—X—CO—Y—Z; and a hydrogel thereof. Here, X is a C1-10 hydrocarbon group, Y is a polyalkylene oxide having oxygen atoms at both ends, and Z is a C1-24 hydrocarbon group or —CO—R2, with R2 being a C1-23 hydrocarbon group. The hydrogel has excellent viscoelasticity and can be injected into a predetermined location with an injection device such as a syringe, and thus can be advantageously used as a medical gel or an adhesion barrier.

Abstract: Particles according to the invention are made of a viscoelastic medium, are injectable gel particles, and have a size, when subjected to a physiological salt solution, in the range of from 1 to 5 mm. The particles are useful in a soft tissue augmentation implant. The implant comprises particles of a viscoelastic medium, wherein a major volume of the particles are injectable gel particles according to the invention. The implant is useful in a method of soft tissue augmentation in a mammal, including man, comprising subepidermal administration at a site in said mammal where soft tissue augmentation is desirable, of an implant according to the invention.

Abstract: The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.

Abstract: Provided herein re a composition and a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.

Abstract: Preparation and use of synthetic trisaccharides useful for the preparation of synthetic heparinoids.

Abstract: The invention relates to a polysaccharide gel of natural origin for dermatological use that comprises an aqueous solution of the polysaccharide of 0.1 to 5% by weight/volume, for example hyaluronic acid, and a viscous and strongly hydrophilic biocompatible alcohol at 0.5-5% by weight/volume, for example glycerol, and optionally the adjuvants that are commonly used in dermatology. The gel is prepared by mixing the polysaccharide solution and the strongly hydrophilic viscous alcohol before sterilizing the entire mixture by, for example, moist heat.

Abstract: A method for inhibiting cellular proliferation of fibroblasts and/or glioma cells in a mammal includes administering a composition to a mammal wherein the composition includes an amount of an anionic polymer and an anti-platelet agent effective to inhibit cellular proliferation of fibroblasts and gliomas in the mammal.

Abstract: The present invention relates to a hyaluronic acid-nucleic acid conjugate for the development of in vivo nucleic acid delivery system, and the development of nucleic acid delivery system using the same. Specifically, a hyaluronic acid-nucleic acid complex wherein a hyaluronic acid-alkylenediamine conjugate and nucleic acid are connected by a disulfide bond; a composition for nucleic acid delivery comprising the hyaluronic acid-nucleic acid complex as an active ingredient; a method for preparing the hyaluronic acid-nucleic acid complex; and a method for in vivo delivery of nucleic acid, comprising administering the hyaluronic acid-nucleic acid complex to a subject are provided.

Abstract: A cysteine hydrazide nicotinamide (Cyhn) reagent designed for the enrichment of bacterial glycoproteins is provided. Methods for purification of free oligosaccharides and their analysis are also provided.

Abstract: [Problem to be Solved] The importance of sugar chains having ?2,3- or ?2,6-linked sialic acid at their non-reducing ends is known. Industrial production has been demanded for these sugar chain compounds. Particularly, the production of glycoprotein drugs or the like inevitably requires producing in quantity sugar chains having homogeneous structures by controlling the linking pattern (?2,6-linkage or ?2,3-linkage) of sialic acid. Particularly, a triantennary or tetraantennary N-type complex sugar chain having sialic acid at each of all non-reducing ends is generally considered difficult to chemically synthesize. There has been no report disclosing that such a sugar chain was chemically synthesized. Furthermore, these sugar chains are also difficult to efficiently prepare enzymatically.

Abstract: Methods for synthesizing a methacrylate-derivatized type-I collagen in which methacrylic acid is reacted with a carboxylic acid activating reagent in the presence of a carbodiimide to form a methacrylic acid with an activated carboxylic acid group, which is then reacted with free amino groups on type-I collagen to form a collagen methacrylamide. Methacrylate-derivatized collagen, cross-linked collagens formed therefrom and products containing the cross-linked collagen are also disclosed.

Abstract: Thermosetting polymeric compositions, such as polyurethane compositions, and related methods are provided. The invention relates to coating and polymer compositions and related methods derived from a biodegradable natural polysaccharide compound such as chitosan, pectin, heparin, and combinations thereof reacted to a cyclic oxide compound, such as an oxetane, oxolane or oxepane compound. The compositions and methods of the present invention exhibit self-repairing properties upon exposure to ultraviolet (UV) light. The compositions and methods of the present invention can be used in many coating applications, such as the transportation, packaging, fashion, and biomedical industries.

Abstract: The present invention provides chemical and chemo-enzymatic methods for the synthesis of a wide array of complex asymmetric multi-antennary glycans.

Abstract: The invention relates generally to oligosaccharide compounds and the use of these compounds as pharmaceuticals for treating diseases or conditions in which it is desirable to inhibit ?-secretase.

Abstract: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency of wound dressing changes.

Abstract: Derivatives are synthesized of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.

Abstract: The invention relates to a pharmaceutical composition free from dexpanthenol, calcium ions and phosphate, comprising at least one calcium chelating agent and at least one opthalmologically compatible viscosity regulator and optionally one or more pharmaceutical excipients. The invention further relates to the use of a calcium chelating agent and an opthalmologically compatible viscosity regulator for the production of a phosphate-free pharmaceutical composition for the treatment and/or prevention of epithelial defects.

Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.

Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.

Abstract: The present invention provides a hyaluronic acid derivative comprising disaccharide units of Formula (I), and a hyaluronic acid derivative/drug conjugate wherein one or more drugs are conjugated to the hyaluronic acid derivative.

Abstract: The present disclosure describes hydrophobically modified nanoparticles and polymeric nanostructures that can be utilized to for the treatment of neuronal injury or neuronal disease in an affected patient, along with methods of forming and using the nanoparticles and nanostructures. Furthermore, the nanoparticles and nanostructures are designed as “dual action” compositions to treat neuronal injury and neuronal disease via repair of damaged membrane and suppression of intracellular inflammation.

Abstract: The present invention relates to purification and use of a novel emulsion stabilizing polysaccharide. In particular, a polyelectrolyte exopolysaccharide with high molecular weight comprising a high molecular weight polymer with a tri-saccharide repeating unit is disclosed. In one aspect of the invention, methods are directed to isolating and purifying a high molecular weight exopolysaccharide (EPS) from a cell supernatant. In another aspect, methods are disclosed for isolating a lipopolysaccharide (LPS) and a high molecular weight Acinetobacter polyelectrolyte exopolysaccharide (APE) from Acinetobacter bacteria. Compositions are also directed to lipid nanoparticles comprising a therapeutic agent encapsulated by a high molecular weight polysaccharide and nanoparticles comprising a therapeutic agent bound to a cationic polysaccharide cross-linked with a polyanion.

Abstract: The present invention provides novel moenomycin analogs as well as pharmaceutical compositions thereof, methods of synthesis, and methods of use in treating an infection by administering an inventive compound to a subject in need thereof. The moenomycin analogs may be prepared synthetically, biosynthetically, or semi-synthetically. The analogs are particularly useful in treating or preventing infections caused by Gram-positive organisms. Certain inventive compounds may have a broader spectrum of coverage, which includes Gram-negative organisms.

Abstract: The invention provides a synthetic C. difficile PS-II cell wall saccharide. The invention also provides a process for purifying C. difficile PS-II saccharide from C. difficile bacterial cells resulting in reduced contamination. The saccharides may be used in vaccines, particularly as conjugates with carrier proteins.

Abstract: Novel aldehyde-functionalized polysaccharide compositions are described that are more stable in aqueous solution than oxidized polysaccharides or other types of polysaccharides containing pendant aldehyde groups. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.

Abstract: Novel aldehyde-functionalized polysaccharide compositions containing pendant dialdehyde groups are described that are more stable in aqueous solution than oxidized polysaccharides. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.

Abstract: According to an embodiment, a method of providing a biopolymer comprises: cryodesiccating a broth, wherein the broth comprises: (A) a biopolymer, wherein the biopolymer is an exopolysaccharide; and (B) a liquid growth medium. According to certain embodiments, the biopolymer is produced by the fermentation of at least one carbohydrate via a microbe. According to an embodiment, the microbe is a bacterium. According to another embodiment, the microbe is a fungus.

Abstract: The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.

Abstract: Disclosed herein is a hyaluronic acid epoxide derivative film comprises a polymer containing a hydroxyl (—OH) terminal group. The film is prepared by allowing an epoxy crosslinker to react with a mixture of hyaluronic acid and a polymer containing a hydroxyl (—OH) terminal group and has improved physical strength, in vivo stability, flexibility, adhesiveness to biological tissue, and biocompatibility.

Abstract: Functionalized Single Wall Carbon Nanotube (SWCNT) complexed with nanochitosan for use in the delivery of bioaffecting substances and diagnostic applications. fSWCNT complexed with the chitosan NG042 were used for delivery of DNA-encoding EGFP reporter protein and peptide. The results demonstrate that shown CNT-chitosan hybrid nanoparticles exhibit significantly higher transfection efficiency in vivo than chitosan alone. Furthermore, the functionalized nanotubes were tested for peptide transfer into HEK293 cells. The results showed that the hybrid nanoparticles efficiently transferred peptides. Together, these results show that hybrid SWCNT-chitosan particles increase DNA and peptide transfer into cells.

Abstract: Body tissue and structures may be protected using a fluid containing a mixture of partially crosslinked polysaccharide and a further crosslinker. The mixture desirably is sprayable, forms a fluid protective layer via in situ crosslinking, desirably does not drip or run from a treatment site, and may avoid the use of more rapidly curing but potentially less bioacceptable crosslinkers at the treatment site.

Abstract: Sterilized aqueous solution comprising 0.04% to 0.8% by weight hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and one or more buffer components selected from the group consisting of boric acid, sodium borate and sodium dihydrogen phosphate. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 4% to 18% by weight of sodium chloride and a pH from 6.4 to 7.2. The solution is also filtered through a filter medium that has an average pore size of 0.25 ?m or less to provide a sterilized high salt, hyaluronic acid solution.

Abstract: The invention relates to polysaccharides grafted with a unit including a carbon-carbon double bond, to polysaccharides grafted with a unit including a carbon-carbon double bond functionalized by a thioether unit, to the methods for preparing said compounds, to the compositions including such compounds and to the materials including such materials or compositions.

Abstract: An outer layer having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. The intermingling of the guest and host includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between. Also a method of producing an outer layer having such an entanglement, including the steps of: temporarily cloaking at least a portion of the hydrophilic groups of the guest; intermingling at least a portion of the cloaked groups with a porous polymeric structure by diffusing the guest with cloaked groups into at least a portion of the structure's pores; within the pores, crosslinking at least a portion of the molecules of the guest with the guest; and removing the cloaking. Cloaking may be performed by silylation or acylation.

Abstract: An outer layer material having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. Prior to intermingling with the guest, a host blend may be produced to include a physical blend of a hydrophobic polymer host and a maleated hydrophobic co-host (preferably, an anhydride functionalized hydrophobic polymer, whereby the polymer so functionalized, is the same as that selected for the host). The intermingling of the guest and host, or host-co-host blend, includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between.

Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.

Abstract: A new method is described for the oversulfation of (epi)K5-N-sulfates to obtain (epi)K5-amine-O-oversulfates at extremely high degree of sulfation and for the transformation of these intermediates into new N-acyl-(epi)K5-amine-O-oversulfates basically free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field. Also described are pharmaceutical compositions containing, as one of their active ingredients, an (epi)K5-amine-O-oversulfate.

Abstract: The method of the present invention includes a step (i) in which a voltage is applied between first and second electrodes 21 and 22 so that the first electrode serves as a cathode, with the first and second electrodes 21 and 22 being placed in contact with a material that allows ions to move therethrough. The material includes an adsorbent (gel 11) containing a macromolecule that has adsorbed a metal ion. The macromolecule contains the same constitutional units as those contained in a macromolecule extracted from Aphanothece sacrum. The first electrode 21 is placed in contact with the adsorbent in step (i). The metal is deposited on a surface of the first electrode 21 by applying the voltage in step (i).

Abstract: The invention relates to a device for detecting analytes, including a plastic substrate at least partially covered by bonding polymers attached to the substrate in a non-covalent manner, said bonding polymers comprising a polysaccharide backbone provided with aromatic groupings and carboxylic acid groupings.

Abstract: The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.

Abstract: The present invention relates to novel synthetic polysaccharides with antithrombotic activity, having at least one covalent bond with an amino chain, and to the preparation method thereof and to the therapeutic use thereof.

Abstract: HA-based functional probes and a multiplexed targeting strategy for detection and isolation of invasive subpopulations in breast cancer cell lines. Methods for using HA metabolism for profiling and sorting breast cancer heterogeneity. As such, HA-based functional probes have appropriate targeting capacity and safety profiles for development as imaging and therapeutic agents for following repair and neoplastic disease processes such as breast cancer.

Abstract: This invention relates generally to threads of hyaluronic acid, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, dermal fillers), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like.

Abstract: The present invention relates to a novel complex, obtainable by mixing hyaluronic acid or a salt thereof and chondroitin sulphate or a salt thereof, and forming an aqueous solution of said mixture, which is further subjected to a drying process. The invention also relates to various compositions and formulations comprising the complex of the invention, process for obtaining said complex and uses thereof.

Abstract: A polymer containing an N-linked sialo-glycan wherein a sialo-glycan is condensed to a ?-polyglutamic acid using a chemical compound having an amino group on one end and a carboxyl group on another end and represented by the structural formula (I). Formula (I) (In the formula, Z means a hydroxy group or a residue represented by the formula (II), and n represents an integer of 10 or more, with the proviso that any one or more of the Z's is represented by the formula in (II).) Formula (II) (In the formula, X means a hydroxy group or an acetylamino group, Y1 and Y2 mean a hydroxyl group or an N-acetylneuraminic acid residue, L means a hydrocarbon, an m represents 0 or an integer of 1 or 2, with the proviso that Y1 and Y2 are not the same.

Abstract: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body.

Abstract: The invention discloses a method for producing a hemostatic composition comprising mixing a biocompatible polymer suitable for use in hemostasis and a genipin-type crosslinker, crosslinking said polymer by said genipin-type crosslinker to obtain a crosslinked biocompatible polymer, and finishing said crosslinks polymer to a pharmaceutically acceptable hemostatic composition, new hemostatic compositions and methods for using such compositions.

Abstract: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body.